AGÕæÈ˹ٷ½

STOCK TITAN

U.S. Physical Therapy Reports First Quarter 2025 Results

Rhea-AI Impact
(Moderate)
Rhea-AI Sentiment
(Neutral)
Tags

Reports Record First Quarter Patient Volume

HOUSTON--(BUSINESS WIRE)-- U.S. Physical Therapy, Inc. (“USPH� or the “Company�) (NYSE: USPH), a national operator of outpatient physical therapy clinics and provider of industrial injury prevention services, today reported results for the first quarter ended March 31, 2025.

FINANCIAL HIGHLIGHTS

  • Adjusted EBITDA (1), a non-Generally Accepted Accounting Principles (“GAAPâ€�) measure, was $19.5 million for the three months ended March 31, 2025 (â€�2025 First Quarterâ€�), an increase of $2.8 million, or 16.5%, from $16.8 million in the three months ended March 31, 2024 (â€�2024 First Quarterâ€�) primarily driven by acquisitions since the prior year period and an increase in net patient revenue per visit.
  • Net income attributable to USPH’s shareholders (“USPH Net Incomeâ€�), a GAAP measure, was $9.9 million for the 2025 First Quarter compared to $8.0 million in the 2024 First Quarter. In accordance with GAAP, the revaluation of noncontrolling interest, net of taxes, is not included in net income but is charged directly to retained earnings. However, this change is included in the computation of earnings per share. Earnings per share was $0.80 for the 2025 First Quarter compared to $0.46 for the 2024 First Quarter.
  • Operating Results (1), a non-GAAP measure, was $7.3 million in the 2025 First Quarter compared to $7.7 million in the 2024 First Quarter. On a per share basis, Operating Results was $0.48 in the 2025 First Quarter compared to $0.51 in the 2024 First Quarter.
  • Total revenue from physical therapy operations for the 2025 First Quarter increased $22.0 million, or 16.4%, to $156.4 million.
  • Net rate per patient visit for the 2025 First Quarter was $105.66, increasing $2.29 per visit from $103.37 for the 2024 First Quarter, despite the approximate 2.9% Medicare rate reduction which went into effect on January 1, 2025. Net rate per patient visit also increased sequentially by $0.93 from $104.73 for the three months ended December 31, 2024. The increase in net rate per patient visit reflects the Company’s strategic priority of increasing reimbursement rates through contract negotiations with commercial and other payors as well as growing workers compensation as a percent of the Company’s overall mix of business.
  • Average daily patient visits per clinic was an all-time first quarter high of 31.4 for the 2025 First Quarter compared to 29.5 in the 2024 First Quarter. Total patient visits were 1,443,805 in the 2025 First Quarter, a 13.9% increase from the 2024 First Quarter.
  • Industrial injury prevention services (“IIPâ€�) revenue was $27.4 million for the 2025 First Quarter, an increase of 28.8% as compared to the 2024 First Quarter. IIP gross profit was $5.6 million in the 2025 First Quarter, an increase of $1.3 million, or 29.1%, from $4.3 million in the 2024 First Quarter.
  • During the 2025 First Quarter, the Company added 14 clinics and closed seven clinics bringing its total owned and/or managed clinic count to 773 as of March 31, 2025, compared to 720 as of March 31, 2024.
  • On February 28, 2025, the Company acquired a 65% equity interest in a three-clinic practice with the practice owners retaining a 35% equity interest. The business currently generates $4.3 million in annual revenue and 23,000 in annual visits.
  • On April 30, 2025, the Company announced the acquisition of an outpatient home care physical and speech therapy practice through its 50%-owned subsidiary, MSO Metro, LLC. The practice currently generates approximately $2.1 million in annual revenue.
  • The Company’s Board of Directors declared a quarterly dividend of $0.45 per share payable on June 13, 2025, to shareholders of record on May 23, 2025.

___________________________

(1)

These are non-GAAP Measures. See pages 11 to 13 of this release for the definition and reconciliation of Adjusted EBITDA, Operating Results and other non-GAAP measures to the most directly comparable GAAP measure.

MANAGEMENT’S COMMENTS

Chris Reading, Chief Executive Officer, said, “Despite our weather-impacted start, we had strong referral and visit demand which accelerated nicely as the quarter progressed. Importantly, our insurance renegotiations and workers compensation efforts are giving us a lift as we enter one of the busiest seasonal periods of the year. While we have more work to do, we are encouraged by our start and committed to further progress.�

2025 First Quarter Versus 2024 First Quarter

Additional supplemental tables of financial and performance metrics are presented on page 14 of this release.

Physical Therapy Operations

Three Months Ended

Ìý

Variance

Ìý

March 31, 2025

Ìý

March 31, 2024

Ìý

$

Ìý

%

Ìý

(In thousands, except percentages)

Ìý

Ìý

Ìý

Ìý

Ìý

Revenue related to:

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Mature Clinics (1)

$

126,620

Ìý

$

128,501

Ìý

$

(1,881

)

(1.5

)%

Clinic additions (2)

Ìý

25,667

Ìý

Ìý

44

Ìý

Ìý

25,623

Ìý

*

(7)

Clinics sold or closed (3)

Ìý

260

Ìý

Ìý

2,530

Ìý

Ìý

(2,270

)

*

(7)

Net patient revenue

Ìý

152,547

Ìý

Ìý

131,075

Ìý

Ìý

21,472

Ìý

16.4

%

Other (4)

Ìý

3,861

Ìý

Ìý

3,350

Ìý

Ìý

511

Ìý

15.3

%

Total

Ìý

156,408

Ìý

Ìý

134,425

Ìý

Ìý

21,983

Ìý

16.4

%

Operating costs (5)

Ìý

130,940

Ìý

Ìý

110,361

Ìý

Ìý

20,579

Ìý

18.6

%

Gross profit

$

25,468

Ìý

$

24,064

Ìý

$

1,404

Ìý

5.8

%

Financial and operating metrics (not in thousands):

Net rate per patient visit (1)

$

105.66

Ìý

$

103.37

Ìý

$

2.29

Ìý

2.2

%

Patient visits (1)

Ìý

1,443,805

Ìý

Ìý

1,268,002

Ìý

Ìý

175,803

Ìý

13.9

%

Average daily visits per clinic (1)

Ìý

31.4

Ìý

Ìý

29.5

Ìý

Ìý

1.9

Ìý

6.4

%

Gross margin

Ìý

16.3

%

Ìý

17.9

%

Salaries and related costs per visit, clinics (6)

$

63.53

Ìý

$

61.42

Ìý

$

2.11

Ìý

3.4

%

Operating costs per visit, clinics (6)

$

89.28

Ìý

$

85.50

Ìý

$

3.78

Ìý

4.4

%

Ìý

(1) See Glossary of Terms - Revenue Metrics for definition.

(2) Includes 14 clinics added during the 2025 First Quarter and 103 added during the year ended December 31, 2024.

(3) Includes 7 clinics closed during the 2025 First Quarter and 45 clinics closed during the year ended December 31, 2024.

(4) Includes revenues from management contracts.

(5) Includes costs from management contracts.

(6) Excludes costs from management contracts and $0.1 million of certain incentive costs related to the Metro acquisition. Please refer to the reconciliation of non-GAAP measures to the most directly comparable GAAP measure on page 13.

(7) Not meaningful.

Ìý

Net revenue from physical therapy operations increased $22.0 million, or 16.4%, to $156.4 million for the 2025 First Quarter from $134.4 million for the 2024 First Quarter. This increase was due to the increase in visits from the 53 net clinics added since the comparable prior year period and an increase in net rate per patient visit, which reflects the Company’s strategic priority of increasing reimbursement rates through contract negotiations with commercial and other payors as well as growing workers compensation as a percent of the Company’s overall mix of business. Net rate per patient visit for the 2025 First Quarter was $105.66, increasing $2.29 per visit from $103.37 for the 2024 First Quarter, despite the approximate 2.9% Medicare rate reduction which went into effect on January 1, 2025. Net rate per patient visit also increased sequentially by $0.93 from $104.73 for the three months ended December 31, 2024.

Operating costs from physical therapy operations increased $20.6 million, or 18.6%, to $130.9 million in the 2025 First Quarter from $110.4 million in the 2024 First Quarter primarily driven by the 53 net clinics added since the comparable prior year period. Salaries and related costs per visit was $63.53 in the 2025 First Quarter compared to $61.42 in the 2024 First Quarter while total operating costs per visit was $89.28 compared to $85.50 over the same periods, respectively.

Gross profit from physical therapy operations in the 2025 First Quarter was $25.5 million with a gross profit margin of 16.3% compared to $24.1 million with a gross profit margin of 17.9% in the 2024 First Quarter.

Industrial Injury Prevention Services

Three Months Ended

Ìý

Variance

March 31, 2025

Ìý

March 31, 2024

Ìý

$

Ìý

%

(In thousands, except percentages)

Net revenue

$

27,380

Ìý

$

21,250

Ìý

$

6,130

28.8

%

Operating costs

Ìý

21,783

Ìý

Ìý

16,913

Ìý

Ìý

4,870

28.8

%

Gross profit

$

5,597

Ìý

$

4,337

Ìý

$

1,260

29.1

%

Ìý

Gross margin

Ìý

20.4

%

Ìý

20.4

%

Ìý

Ìý

IIP revenue increased $6.1 million, or 28.8%, to $27.4 million for the 2025 First Quarter as compared to $21.3 million for the 2024 First Quarter. Gross profit from IIP operations in the 2025 First Quarter increased $1.3 million, or 29.1%, to $5.6 million from $4.3 million in the 2024 First Quarter. The gross profit margin from IIP operations was 20.4% in each of the 2025 First Quarter and 2024 First Quarter. Excluding the IIP acquisition made in April 2024, IIP revenue increased by $3.2 million or 15.1% in the 2025 First Quarter and gross profit increased $0.6 million or 13.1% in the 2025 First Quarter over the comparable prior year period.

Corporate Office and Other Expenses

Corporate office costs increased to $16.2 million in the 2025 First Quarter from $14.1 million in the 2024 First Quarter. This increase was primarily to support the larger number of clinics as well as expenses related to the integration of the Company’s recent acquisitions. As a ratio to net revenue, corporate office costs improved to 8.8% in the 2025 First Quarter compared to 9.0% in the 2024 Fourth Quarter.

The Company revalued contingent consideration related to certain acquisitions and recognized a net non-cash gain (a decrease in the related liabilities) of $4.8 million in the 2025 First Quarter compared to $0.6 million in the 2024 First Quarter.

Operating income was $19.6 million for the 2025 First Quarter compared to $14.9 million for the 2024 First Quarter, an increase of 31.6% over the comparable period.

Interest expense increased by $0.3 million to $2.3 million for the 2025 First Quarter compared to $2.0 million in the 2024 First Quarter due to a higher average outstanding balance on our revolving credit facility in the 2025 First Quarter. The interest rate associated with borrowings on the Company’s credit facility was 4.9% for the 2025 First Quarter and 4.7% for the 2024 First Quarter, with an all-in effective interest rate, including all associated costs of 5.5% and 5.3% over the same periods, respectively.

Interest income was less than $0.1 million during the 2025 First Quarter compared to $1.5 million in the 2024 First Quarter as the cash on the balance sheet at the end of the 2024 First Quarter has been deployed into acquisitions since that time.

The Company revalued a put-right liability related to the future purchase of an IIP business and recognized a net non-cash expense (an increase in the related liability) of $0.4 million in the 2025 First Quarter compared to $0.1 million in the 2024 First Quarter.

The provision for income taxes was $3.9 million in the 2025 First Quarter compared to $3.1 million during the 2024 First Quarter while the effective tax rate was 28.1% in each of the same periods, respectively.

USPH Net Income and Non-GAAP Measures

Net income attributable to non-controlling interest (temporary and permanent) was $3.6 million in both the 2025 First Quarter and the 2024 First Quarter.

USPH Net Income was $9.9 million for the 2025 First Quarter compared to $8.0 million in the 2024 First Quarter. In accordance with GAAP, the revaluation of redeemable noncontrolling interest, net of taxes, is not included in net income but is charged directly to retained earnings; however, this change is included in the computation of earnings per share. Earnings per share was $0.80 for the 2025 First Quarter compared to $0.46 for the 2024 First Quarter.

Non-GAAP Adjusted EBITDA (1) was $19.5 million for the 2025 First Quarter, an increase of $2.8 million or 16.5%, from $16.8 million for the 2024 First Quarter. Non-GAAP Operating Results (1) was $7.3 million, or $0.48 per share, in the 2025 First Quarter compared to $7.7 million, or $0.51 per share, in the 2024 First Quarter.

___________________________

(1)

These are Non-GAAP Measures. See pages 11 to 12 of this release for the definition and reconciliation of Adjusted EBITDA and Operating Results measures to the most directly comparable GAAP measure.

BALANCE SHEET AND CASH FLOW

Total cash and cash equivalents were $39.2 million as of March 31, 2025, compared to $41.4 million as of December 31, 2024, and $132.3 million as of March 31, 2024. The Company had $164.9 million in outstanding borrowings and $147.0 million in available credit under its credit facilities as of March 31, 2025. This compares to $151.6 million of outstanding borrowings and $164.0 million in available credit under its credit facilities as of December 31, 2024.

RECENT ACQUISITIONS

On February 28, 2025, the Company acquired a 65% equity interest in a three-clinic practice with the original practice owners retaining 35% equity interest. The business currently generates $4.3 million in annual revenue and 23,000 in annual visits.

On April 30, 2025, the Company announced the acquisition of an outpatient home care physical and speech therapy practice through its 50%-owned subsidiary, MSO Metro, LLC. The practice currently generates approximately $2.1 million in annual revenue.

The Company’s strategy is to continue acquiring multi-clinic outpatient physical therapy practices, to develop outpatient physical therapy clinics as satellites in existing partnerships and to continue acquiring companies that provide industrial injury prevention services.

QUARTERLY DIVIDEND

The Company’s Board of Directors declared a quarterly dividend of $0.45 per share payable on June 13, 2025, to shareholders of record on May 23, 2025.

CONFERENCE CALL INFORMATION

U.S. Physical Therapy’s management will host a conference call at 10:30 a.m. ET / 9:30 a.m. CT, on May 8, 2025, to discuss the Company’s financial results for the first quarter ended March 31, 2025. Interested parties may participate in the call by dialing (800) 274-8461 (Primary) or (203) 518-9814 (Alternate) and conference ID of USPHQ125. Please call approximately 10 minutes before the call is scheduled to begin. To listen to the live call, go to the Company’s website at at least 15 minutes early to register, download and install any necessary audio software. If you are unable to listen live, a playback of the conference call can be accessed until August 7, 2025, on the Company’s website.

FORWARD LOOKING STATEMENTS

This press release contains statements that are considered to be forward-looking within the meaning under Section 21E of the Securities Exchange Act of 1934, as amended. These statements contain forward-looking information relating to the financial condition, results of operations, plans, objectives, future performance and business of our Company. These statements (often using words such as “believes,� “expects,� “intends,� “plans,� “appear,� “should� and similar words) involve risks and uncertainties that could cause actual results to differ materially from those we expect. Included among such statements may be those relating to new clinics, availability of personnel and the reimbursement environment. The forward-looking statements are based on our current views and assumptions and actual results could differ materially from those anticipated in such forward-looking statements as a result of certain risks, uncertainties, and factors, which include, but are not limited to:

  • changes in Medicare rules and guidelines and reimbursement or failure of our clinics to maintain their Medicare certification and/or enrollment status;
  • revenue we receive from Medicare and Medicaid being subject to potential retroactive reduction;
  • changes in reimbursement rates or payment methods from third party payors including government agencies, and changes in the deductibles and co-pays owed by patients;
  • private third-party payors for our services may adopt payment policies that could limit our future revenue and profitability;
  • compliance with federal and state laws and regulations relating to the privacy of individually identifiable patient information, and associated fines and penalties for failure to comply;
  • compliance with state laws and regulations relating to the corporate practice of medicine and fee splitting, and associated fines and penalties for failure to comply;
  • competitive, economic or reimbursement conditions in our markets which may require us to reorganize or close certain clinics and thereby incur losses and/or closure costs including the possible write-down or write-off of goodwill and other intangible assets;
  • the impact of future public health crises and epidemics/pandemics, such as was the case with the novel strain of COVID-19 and its variants;
  • certain of our acquisition agreements contain put-rights related to a future purchase of significant equity interests in our subsidiaries or in a separate company;
  • the impact of future vaccinations and/or testing mandates at the federal, state and/or local level, which could have an adverse impact on staffing, revenue, costs and the results of operations;
  • our debt and financial obligations could adversely affect our financial condition, our ability to obtain future financing and our ability to operate our business;
  • changes as the result of government enacted national healthcare reform;
  • the ability to control variable interest entities for which we do not have a direct ownership;
  • business and regulatory conditions including federal and state regulations;
  • governmental and other third party payor inspections, reviews, investigations and audits, which may result in sanctions or reputational harm and increased costs;
  • revenue and earnings expectations;
  • contingent consideration provisions in certain of our acquisition agreements, the value of which may impact future financial results;
  • legal actions, which could subject us to increased operating costs and uninsured liabilities;
  • general economic conditions, including but not limited to inflationary and recessionary periods;
  • actual or perceived events involving banking volatility or limited liability, defaults or other adverse developments that affect the U.S or the international financial systems, may result in market wide liquidity problems which could have a material and adverse impact on our available cash and results of operations;
  • our business depends on hiring, training, and retaining qualified employees;
  • availability and cost of qualified physical therapists;
  • competitive environment in the industrial injury prevention services business, which could result in the termination or non-renewal of contractual service arrangements and other adverse financial consequences for that service line;
  • our ability to identify and complete acquisitions, and the successful integration of the operations of the acquired businesses;
  • impact on the business and cash reserves resulting from retirement or resignation of key partners and resulting purchase of their non-controlling interest (minority interests);
  • maintaining our information technology systems with adequate safeguards to protect against cyber-attacks;
  • a security breach of our or our third party vendorsâ€� information technology systems may subject us to potential legal action and reputational harm and may result in a violation of the Health Insurance Portability and Accountability Act of 1996 of the Health Information Technology for Economic and Clinical Health Act;
  • maintaining clients for which we perform management, industrial injury prevention related services, and other services, as a breach or termination of those contractual arrangements by such clients could cause operating results to be less than expected;
  • maintaining adequate internal controls;
  • maintaining necessary insurance coverage;
  • availability, terms, and use of capital; and
  • weather and other seasonal factors.

Many factors are beyond our control. Given these uncertainties, you should not place undue reliance on our forward-looking statements. For additional information regarding these and other risks and uncertainties, that could cause actual results to differ materially from those contained in our forward-looking statements, please refer to “Risk Factors� in our Annual Report on Form 10-K for the year ended December 31, 2024, filed with the Securities and Exchange Commission (“SEC�) on March 3, 3025 and any risk factors contained in subsequent quarterly and annual reports we file with the SEC. Our forward-looking statements represent our estimates and assumptions only as of the date of this report. Except as required by law, we are under no obligation to update any forward-looking statement as a result of new information, future events, or otherwise, except as required by law.

GLOSSARY OF TERMS � REVENUE METRICS

Mature clinics are clinics opened or acquired prior to January 1, 2024, and are still operating as of the balance sheet date.

Net rate per patient visit is net patient revenue related to our physical therapy operations divided by total number of patient visits (defined below) during the periods presented.

Patient visits is the number of unique patient visits during the periods presented.

Average daily visits per clinic is patient visits divided by the number of days in which normal business operations were conducted during the periods presented and further divided by the average number of clinics in operation during the periods presented.

ABOUT U.S. PHYSICAL THERAPY, INC.

Founded in 1990, U.S. Physical Therapy, Inc. owns and/or manages 773 outpatient physical therapy clinics in 44 states. USPH clinics provide preventative and post-operative care for a variety of orthopedic-related disorders and sports-related injuries, treatment for neurologically-related injuries and rehabilitation of injured workers. USPH also has an industrial injury prevention business which provides onsite services for clients� employees including injury prevention and rehabilitation, performance optimization, post-offer employment testing, functional capacity evaluations, and ergonomic assessments.

More information about U.S. Physical Therapy, Inc. is available at . The information included on that website is not incorporated into this press release.

Ìý
Ìý
Ìý

U.S. PHYSICAL THERAPY, INC. AND SUBSIDIARIES
UNAUDITED CONSOLIDATED STATEMENTS OF INCOME
(IN THOUSANDS, EXCEPT PER SHARE AMOUNTS)
Ìý

Ìý

Three Months Ended

March 31, 2025

Ìý

March 31, 2024

Ìý

Net patient revenue

$

152,547

Ìý

$

131,075

Ìý

Other revenue

Ìý

31,241

Ìý

Ìý

24,600

Ìý

Net revenue

Ìý

183,788

Ìý

Ìý

155,675

Ìý

Operating cost

Salaries and related costs

Ìý

111,249

Ìý

Ìý

93,731

Ìý

Rent, supplies, contract labor and other

Ìý

33,844

Ìý

Ìý

27,904

Ìý

Depreciation and amortization

Ìý

5,540

Ìý

Ìý

3,885

Ìý

Provision for credit losses

Ìý

1,848

Ìý

Ìý

1,627

Ìý

Clinic closure costs - lease and other

Ìý

242

Ìý

Ìý

127

Ìý

Total operating cost

Ìý

152,723

Ìý

Ìý

127,274

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Gross profit

Ìý

31,065

Ìý

Ìý

28,401

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Corporate office costs

Ìý

16,245

Ìý

Ìý

14,085

Ìý

Gain on change in fair value of contingent earn-out consideration

Ìý

(4,822

)

Ìý

(612

)

Operating income

Ìý

19,642

Ìý

Ìý

14,928

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Other (expense) income

Interest expense, debt and other

Ìý

(2,279

)

Ìý

(1,968

)

Interest income from investments

Ìý

24

Ìý

Ìý

1,543

Ìý

Change in revaluation of put-right liability

Ìý

(404

)

Ìý

(80

)

Equity in earnings of unconsolidated affiliate

Ìý

393

Ìý

Ìý

271

Ìý

Loss on sale of a partnership

Ìý

(123

)

Ìý

-

Ìý

Other

Ìý

75

Ìý

Ìý

62

Ìý

Total other expense

Ìý

(2,314

)

Ìý

(172

)

Income before taxes

Ìý

17,328

Ìý

Ìý

14,756

Ìý

Ìý

Provision for income taxes

Ìý

3,860

Ìý

Ìý

3,139

Ìý

Net income

Ìý

13,468

Ìý

Ìý

11,617

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Less: Net income attributable to non-controlling interest

Redeemable non-controlling interest - temporary equity

Ìý

(2,012

)

Ìý

(2,227

)

Non-controlling interest - permanent equity

Ìý

(1,557

)

Ìý

(1,344

)

Ìý

(3,569

)

Ìý

(3,571

)

Ìý

Net income attributable to USPH shareholders

$

9,899

Ìý

$

8,046

Ìý

Ìý

Basic and diluted earnings per share attributable to USPH shareholders (1)

$

0.80

Ìý

$

0.46

Ìý

Ìý

Shares used in computation - basic and diluted

Ìý

15,132

Ìý

Ìý

15,017

Ìý

Ìý

Dividends declared per common share

$

0.45

Ìý

$

0.44

Ìý

(1)

See page 12 of this press release for the calculation of basic and diluted earnings per share.

Ìý
Ìý
Ìý
Ìý

U. S. PHYSICAL THERAPY, INC. AND SUBSIDIARIES
UNAUDITED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
(IN THOUSANDS)
Ìý

Ìý

Three Months Ended

March 31, 2025

Ìý

March 31, 2024

Ìý

Net income

$

13,468

Ìý

$

11,617

Ìý

Other comprehensive gain:

Unrealized (loss) gain on cash flow hedge

Ìý

(1,331

)

Ìý

1,781

Ìý

Tax effect at statutory rate (federal and state)

Ìý

340

Ìý

Ìý

(455

)

Comprehensive income

$

12,477

Ìý

$

12,943

Ìý

Comprehensive income attributable to non-controlling interest

Ìý

(3,569

)

Ìý

(3,571

)

Comprehensive income attributable to USPH shareholders

$

8,908

Ìý

$

9,372

Ìý

Ìý
Ìý
Ìý
Ìý

U. S. PHYSICAL THERAPY, INC. AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEET
(IN THOUSANDS, EXCEPT SHARES AND PER SHARE AMOUNTS)
Ìý

Ìý

March 31, 2025

Ìý

December 31, 2024

(unaudited)

Ìý

Ìý

ASSETS

Ìý

Ìý

Ìý

Current assets:

Ìý

Ìý

Ìý

Cash and cash equivalents

$

39,183

Ìý

$

41,362

Ìý

Patient accounts receivable, less provision for credit losses of $3,620 and $3,506, respectively

Ìý

64,760

Ìý

Ìý

59,040

Ìý

Accounts receivable - other

Ìý

26,136

Ìý

Ìý

26,626

Ìý

Other current assets

Ìý

15,274

Ìý

Ìý

10,555

Ìý

Total current assets

Ìý

145,353

Ìý

Ìý

137,583

Ìý

Ìý

Fixed assets:

Furniture and equipment

Ìý

68,802

Ìý

Ìý

68,128

Ìý

Leasehold improvements

Ìý

53,504

Ìý

Ìý

51,105

Ìý

Fixed assets, gross

Ìý

122,306

Ìý

Ìý

119,233

Ìý

Less accumulated depreciation and amortization

Ìý

(89,542

)

Ìý

(87,093

)

Fixed assets, net

Ìý

32,764

Ìý

Ìý

32,140

Ìý

Operating lease right-of-use assets

Ìý

133,197

Ìý

Ìý

133,936

Ìý

Investment in unconsolidated affiliate

Ìý

12,273

Ìý

Ìý

12,190

Ìý

Goodwill

Ìý

674,387

Ìý

Ìý

667,152

Ìý

Other identifiable intangible assets, net

Ìý

177,328

Ìý

Ìý

179,311

Ìý

Other assets

Ìý

4,385

Ìý

Ìý

5,155

Ìý

Total assets

$

1,179,687

Ìý

$

1,167,467

Ìý

Ìý

Ìý

Ìý

LIABILITIES, REDEEMABLE NON-CONTROLLING INTEREST, USPH SHAREHOLDERS� EQUITY AND NON-CONTROLLING INTEREST

Ìý

Ìý

Current liabilities:

Ìý

Ìý

Accounts payable - trade

$

6,088

Ìý

$

5,936

Ìý

Accrued expenses

Ìý

68,326

Ìý

Ìý

59,513

Ìý

Current portion of operating lease liabilities

Ìý

40,124

Ìý

Ìý

39,835

Ìý

Current portion of term loan and notes payable

Ìý

9,257

Ìý

Ìý

10,999

Ìý

Total current liabilities

Ìý

123,795

Ìý

Ìý

116,283

Ìý

Notes payable, net of current portion

Ìý

387

Ìý

Ìý

903

Ìý

Revolving facility

Ìý

28,000

Ìý

Ìý

11,000

Ìý

Term loan, net of current portion and deferred financing costs

Ìý

128,851

Ìý

Ìý

130,627

Ìý

Deferred taxes

Ìý

34,055

Ìý

Ìý

29,465

Ìý

Operating lease liabilities, net of current portion

Ìý

100,688

Ìý

Ìý

101,868

Ìý

Other long-term liabilities

Ìý

4,903

Ìý

Ìý

18,275

Ìý

Total liabilities

Ìý

420,679

Ìý

Ìý

408,421

Ìý

Ìý

Redeemable non-controlling interest - temporary equity

Ìý

260,047

Ìý

Ìý

269,025

Ìý

Ìý

Commitments and Contingencies

Ìý

U.S. Physical Therapy, Inc. ("USPH") shareholders� equity:

Preferred stock, $.01 par value, 500,000 shares authorized, no shares issued and outstanding

Ìý

-

Ìý

Ìý

-

Ìý

Common stock, $.01 par value, 20,000,000 shares authorized, 17,406,426 and 17,309,120 shares issued, respectively

Ìý

172

Ìý

Ìý

172

Ìý

Additional paid-in capital

Ìý

292,773

Ìý

Ìý

290,321

Ìý

Accumulated other comprehensive gain

Ìý

1,783

Ìý

Ìý

2,799

Ìý

Retained earnings

Ìý

234,161

Ìý

Ìý

227,265

Ìý

Treasury stock at cost, 2,214,737 shares

Ìý

(31,628

)

Ìý

(31,628

)

Total USPH shareholders� equity

Ìý

497,261

Ìý

Ìý

488,929

Ìý

Non-controlling interest - permanent equity

Ìý

1,700

Ìý

Ìý

1,092

Ìý

Total USPH shareholders' equity and non-controlling interest - permanent equity

Ìý

498,961

Ìý

Ìý

490,021

Ìý

Total liabilities, redeemable non-controlling interest,

USPH shareholders' equity and non-controlling interest - permanent equity

$

1,179,687

Ìý

$

1,167,467

Ìý

Ìý
Ìý
Ìý
Ìý

U. S. PHYSICAL THERAPY, INC. AND SUBSIDIARIES
UNAUDITED CONSOLIDATED STATEMENTS OF CASH FLOWS
(IN THOUSANDS)
Ìý

Ìý

Three Months Ended

March 31, 2025

March 31, 2024

OPERATING ACTIVITIES

Net income including non-controlling interest

$

13,468

Ìý

$

11,617

Ìý

Adjustments to reconcile net income including non-controlling interest to net cash provided by operating activities:

Depreciation and amortization

Ìý

5,867

Ìý

Ìý

4,095

Ìý

Provision for credit losses

Ìý

1,848

Ìý

Ìý

1,627

Ìý

Equity-based awards compensation expense

Ìý

1,771

Ìý

Ìý

1,997

Ìý

Amortization of debt issue costs

Ìý

106

Ìý

Ìý

106

Ìý

Change in deferred income taxes

Ìý

5,242

Ìý

Ìý

1,943

Ìý

Change in revaluation of put-right liability

Ìý

404

Ìý

Ìý

80

Ìý

Gain on change in fair value of contingent earn-out consideration

Ìý

(4,822

)

Ìý

(612

)

Equity of earnings in unconsolidated affiliate

Ìý

(393

)

Ìý

(271

)

Loss on sale of fixed assets

Ìý

-

Ìý

Ìý

5

Ìý

Loss on sale of a partnership

Ìý

123

Ìý

Ìý

-

Ìý

Changes in operating assets and liabilities:

Increase in patient accounts receivable

Ìý

(7,341

)

Ìý

(5,124

)

Decrease (increase) in accounts receivable - other

Ìý

774

Ìý

Ìý

(3,985

)

Increase in other current and long term assets

Ìý

(6,209

)

Ìý

(433

)

Decrease in accounts payable and accrued expenses

Ìý

(14,229

)

Ìý

(6,678

)

(Decrease) increase in long term liabilities

Ìý

(1,284

)

Ìý

52

Ìý

Net cash (used in) provided by operating activities

Ìý

(4,675

)

Ìý

4,419

Ìý

Ìý

INVESTING ACTIVITIES

Purchase of fixed assets

Ìý

(2,579

)

Ìý

(1,838

)

Purchase of majority interest in businesses, net of cash acquired

Ìý

(4,211

)

Ìý

(15,971

)

Purchase of redeemable non-controlling interest, temporary equity

Ìý

(907

)

Ìý

(2,702

)

Purchase of non-controlling interest, permanent equity

Ìý

-

Ìý

Ìý

(498

)

Proceeds from the sale of partnership interest - redeemable non-controlling interest, temporary equity

Ìý

15

Ìý

Ìý

67

Ìý

Proceeds from the sale of non-controlling interest, permanent equity

Ìý

-

Ìý

Ìý

23

Ìý

Proceeds from sale of partnership

Ìý

700

Ìý

Ìý

-

Ìý

Distributions from unconsolidated affiliate

Ìý

310

Ìý

Ìý

367

Ìý

Other

Ìý

44

Ìý

Ìý

88

Ìý

Net cash (used in) investing activities

Ìý

(6,628

)

Ìý

(20,464

)

Ìý

FINANCING ACTIVITIES

Proceeds from revolving facility

Ìý

17,000

Ìý

Ìý

-

Ìý

Distributions to non-controlling interest, permanent and temporary equity

Ìý

(3,653

)

Ìý

(3,160

)

Payments on term loan

Ìý

(3,750

)

Ìý

(938

)

Principal payments on notes payable

Ìý

(473

)

Ìý

(392

)

Net cash provided by (used in) financing activities

Ìý

9,124

Ìý

Ìý

(4,490

)

Ìý

Net (decrease) in cash and cash equivalents

Ìý

(2,179

)

Ìý

(20,535

)

Cash and cash equivalents - beginning of period

Ìý

41,362

Ìý

Ìý

152,825

Ìý

Cash and cash equivalents - end of period

$

39,183

Ìý

$

132,290

Ìý

Ìý

SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION

Cash paid during the period for:

Income taxes

$

7,359

Ìý

$

367

Ìý

Interest paid

Ìý

2,205

Ìý

Ìý

1,844

Ìý

Non-cash investing and financing transactions during the period:

Purchase of businesses - seller financing portion

Ìý

-

Ìý

Ìý

500

Ìý

Purchase of redeemable non-controlling interest, temporary equity, recorded in accrued liabilities

Ìý

6,672

Ìý

Ìý

-

Ìý

Fair market value of initial contingent consideration related to purchase of businesses

Ìý

1,259

Ìý

Ìý

-

Ìý

Notes payable related to purchase of redeemable non-controlling interest, temporary equity

Ìý

89

Ìý

Ìý

-

Ìý

Notes receivable related to sale of redeemable non-controlling interest, temporary equity

Ìý

646

Ìý

Ìý

315

Ìý

Notes receivable related to the sale of non-controlling interest, permanent equity

Ìý

-

Ìý

Ìý

243

Ìý

Offset to notes receivable associated with purchase of redeemable non-controlling interest

Ìý

180

Ìý

Ìý

75

Ìý

Dividends payable to USPH shareholders

Ìý

6,836

Ìý

Ìý

6,630

Ìý

Ìý
Ìý
Ìý

U. S. PHYSICAL THERAPY, INC. AND SUBSIDIARIES
ADJUSTED EBITDA AND OPERATING RESULTS

The following tables provide details of the basic and diluted earnings per share computation and reconcile net income attributable to USPH shareholders calculated in accordance with GAAP to Adjusted EBITDA and Operating Results. The tables also provide a reconciliation of additional non-GAAP measures to the most comparable GAAP measure. Management believes providing Adjusted EBITDA and Operating Results to investors is useful for comparing the Company's period-to-period results as well as for comparing with other similar businesses since most do not have redeemable instruments and therefore have different equity structures. Management uses Adjusted EBITDA and Operating Results, which eliminate certain items described above that can be subject to volatility and unusual costs, as the principal measures to evaluate and monitor financial performance period over period.

Adjusted EBITDA, a non-GAAP measure, is defined as net income attributable to USPH shareholders before interest income, interest expense, taxes, depreciation, amortization, change in fair value of contingent earn-out consideration, changes in revaluation of put-right liability, equity-based awards compensation expense, clinic closure costs, business acquisition related costs, costs related to a one-time financial systems upgrade, loss on sale of a partnership and other income and related portions for non-controlling interests.

Operating Results, a non-GAAP measure, equals net income attributable to USPH shareholders less, changes in revaluation of a put-right liability, clinic closure costs, loss on sale of a partnership, changes in fair value of contingent earn-out consideration, business acquisition related costs, costs related to a one-time financial systems upgrade and any allocations to non-controlling interests, all net of taxes. Operating Results per share also excludes the impact of the revaluation of redeemable non-controlling interest and the associated tax impact.

Adjusted EBITDA and Operating Results are not measures of financial performance under GAAP. Adjusted EBITDA, Operating Results and other non-GAAP measures should not be considered in isolation or as an alternative to, or substitute for, net income attributable to USPH shareholders presented in the consolidated financial statements.

Ìý
Ìý
Ìý

U. S. PHYSICAL THERAPY, INC. AND SUBSIDIARIES
ADJUSTED EBITDA, OPERATING RESULTS AND EARNINGS PER SHARE
(IN THOUSANDS, EXCEPT PER SHARE DATA)
Ìý

Ìý

Ìý

Three Months Ended

Ìý

March 31, 2025

Ìý

March 31, 2024

Ìý

Adjusted EBITDA (a non-GAAP measure)

Net income attributable to USPH shareholders

$

9,899

Ìý

$

8,046

Ìý

Adjustments:

Provision for income taxes

Ìý

3,860

Ìý

Ìý

3,139

Ìý

Depreciation and amortization

Ìý

5,867

Ìý

Ìý

4,095

Ìý

Interest expense, debt and other, net

Ìý

2,279

Ìý

Ìý

1,968

Ìý

Interest income from investments

Ìý

(24

)

Ìý

(1,543

)

Equity-based awards compensation expense

Ìý

1,771

Ìý

Ìý

1,997

Ìý

Change in revaluation of put-right liability

Ìý

404

Ìý

Ìý

80

Ìý

Change in fair value of contingent earn-out consideration

Ìý

(4,822

)

Ìý

(612

)

Clinic closure costs (1)

Ìý

242

Ìý

Ìý

126

Ìý

Business acquisition related costs (2)

Ìý

480

Ìý

Ìý

-

Ìý

ERP implementation costs (3)

Ìý

62

Ìý

Ìý

-

Ìý

Loss on sale of a partnership

Ìý

123

Ìý

Ìý

-

Ìý

Other loss (income)

Ìý

(75

)

Ìý

(62

)

Allocation to non-controlling interests

Ìý

(527

)

Ìý

(463

)

$

19,539

Ìý

$

16,771

Ìý

Ìý

Operating Results (a non-GAAP measure)

Net income attributable to USPH shareholders

$

9,899

Ìý

$

8,046

Ìý

Adjustments:

Change in fair value of contingent earn-out consideration

Ìý

(4,822

)

Ìý

(612

)

Change in revaluation of put-right liability

Ìý

404

Ìý

Ìý

80

Ìý

Clinic closure costs (1)

Ìý

242

Ìý

Ìý

126

Ìý

Business acquisition related costs (2)

Ìý

480

Ìý

Ìý

-

Ìý

ERP implementation costs (3)

Ìý

62

Ìý

Ìý

-

Ìý

Loss on sale of a partnership

Ìý

123

Ìý

Ìý

-

Ìý

Allocation to non-controlling interest

Ìý

(10

)

Ìý

(16

)

Tax effect at statutory rate (federal and state)

Ìý

935

Ìý

Ìý

108

Ìý

$

7,313

Ìý

$

7,732

Ìý

Ìý
Ìý

Operating Results per share (a non-GAAP measure)

$

0.48

Ìý

$

0.51

Ìý

Ìý

Earnings per share

Computation of earnings per share - USPH shareholders:

Net income attributable to USPH shareholders

$

9,899

Ìý

$

8,046

Ìý

Charges to retained earnings:

Revaluation of redeemable non-controlling interest

Ìý

2,903

Ìý

Ìý

(1,439

)

Tax effect at statutory rate (federal and state)

Ìý

(742

)

Ìý

368

Ìý

$

12,060

Ìý

$

6,975

Ìý

Ìý

Earnings per share (basic and diluted)

$

0.80

Ìý

$

0.46

Ìý

Ìý

Shares used in computation - basic and diluted

Ìý

15,132

Ìý

Ìý

15,017

Ìý

___________________________

(1)

Costs associated with the closure of seven and six clinics during the 2025 First Quarter and the 2024 First Quarter, respectively.

(2)

Primarily consists of legal and consulting expenses related to the acquisitions of equity interests in certain partnerships.Ìý

(3)

Consists of costs related to a one-time financial systems upgrade.Ìý

Ìý
Ìý
Ìý
Ìý

U. S. PHYSICAL THERAPY, INC. AND SUBSIDIARIES
RECONCILIATION OF NON-GAAP MEASURES TO THE MOST COMPARABLE GAAP MEASURES
(IN THOUSANDS, EXCEPT PER SHARE DATA AND PERCENTAGES)
Ìý

Ìý

The tables below reconcile other non-GAAP measures to the most directly comparable GAAP measures.Ìý

Ìý

Three Months Ended

March 31, 2025

As Reported

(GAAP)

Ìý

Adjustments (1)

Ìý

As Adjusted

(Non-GAAP)

(in thousands, except percentages)

Segment information - Physical Therapy Operations

Salaries and related costs, clinics (2)

$

91,799

Ìý

$

(75

)

$

91,724

Ìý

Operating costs, clinics (2)

$

128,971

Ìý

$

(75

)

$

128,896

Ìý

Gross profit

$

25,468

Ìý

$

75

Ìý

$

25,543

Ìý

Gross margin

Ìý

16.3

%

*

Ìý

16.3

%

Number of visits

Ìý

1,443,805

Ìý

Ìý

Ìý

Ìý

Ìý

1,443,805

Ìý

Salaries and related costs per visit, clinics

$

63.58

Ìý

Ìý

$

(0.05

)

Ìý

$

63.53

Ìý

Operating costs per visit, clinics

$

89.33

Ìý

Ìý

$

(0.05

)

Ìý

$

89.28

Ìý

___________________________

(1)

Certain incentive costs related to the Metro acquisition. We believe that presenting this information will allow investors to evaluate the performance of the Company's business more objectively.

(2)

Excludes costs related to management contracts.Ìý

* Not meaningful

Ìý
Ìý
Ìý
Ìý

U. S. PHYSICAL THERAPY, INC. AND SUBSIDIARIES
SUPPLEMENTAL FINANCIAL AND PERFORMANCE METRICS
Ìý

Ìý

Revenue MetricsÌý

Ìý

Number of Clinics(2)

Ìý

Net Rate Per Visit(1)

Ìý

Visits(1)

Ìý

Average Visits Per Day(1)

2025

Ìý

2024

Ìý

2025

Ìý

2024

Ìý

2025

Ìý

2024

Ìý

2025

Ìý

2024

Ìý

First quarter

736

679

$105.66

$103.37

1,443,805

1,268,002

31.4

29.5

Second quarter

-

681

-

$105.05

-

1,335,335

-

30.6

Third quarter

-

661

-

$105.65

-

1,317,051

-

30.1

Fourth Quarter

-

729

-

$104.73

-

1,432,801

-

31.7

Year

-

729

-

$104.71

1,443,805

5,353,189

-

30.4

Ìý
Ìý

Clinic Count Roll Forward (2)Ìý

Ìý

Three Months Ended

March 31, 2025

Ìý

March 31, 2024

Number of clinics owned or managed, beginning of period

729

Ìý

671

Ìý

Additions (3)

14

Ìý

14

Ìý

Closed or sold

(7

)

(6

)

Number of clinics owned or managed, end of period

736

679

Ìý

___________________________

(1)

See definition of the metrics above in the Glossary of Terms � Revenue Metrics section on page 6.

(2)

The Company also manages clinics owned by third parties through management contracts. In addition to the clinic count shown above, as of March 31, 2025, the Company managed 37 clinics bringing the total owned/managed clinics to 773. As of March 31, 2024, the Company managed 41 clinics bringing the total owned/managed clinics to 720.Ìý

(3)

Includes clinics added through acquisitions.

Ìý
Ìý

Ìý

U.S. Physical Therapy, Inc.

Carey Hendrickson, Chief Financial Officer

email: [email protected]

Chris Reading, Chief Executive Officer

(713) 297-7000

Three Part Advisors

Joe Noyons

(817) 778-8424

Source: U.S. Physical Therapy, Inc.

U S Physical Therapy

NYSE:USPH

USPH Rankings

USPH Latest News

USPH Latest SEC Filings

USPH Stock Data

1.14B
14.88M
1.94%
105.51%
3.57%
Medical Care Facilities
Services-health Services
United States
HOUSTON